PraxisPro Raises $6M Seed to Bring Specialized AI Sales Training to Life Sciences

New updates have been reported about PraxisPro.

PraxisPro, a sales coaching platform built specifically for life sciences commercial teams, has raised a $6 million seed round to accelerate development of its AI-driven training tools and expand enterprise adoption. Founded by former pharma sales rep and trainer Cam Badger alongside Dr. Benny Alouf and Bhrugu Giri, the company targets a long-standing pain point in pharmaceutical, biotech, and medical device sales: fragmented training, inconsistent coaching, and weak compliance-ready messaging when engaging healthcare providers. Launched in 2023, PraxisPro released its first product in 2025 and now positions itself as a standalone or integrated platform that plugs into existing enterprise software stacks. The latest financing was led by AlleyCorp, with participation from Flybridge, South Loop Ventures, and Zeal Capital Partners, and will be directed primarily into research and development to deepen the platform’s AI capabilities and domain specificity.

PraxisPro develops small, domain-tuned language models trained on life sciences content to reflect the regulatory, clinical, and commercial nuances of provider interactions. On top of these models, the company has built an AI agent that enables sales reps to role‑play realistic conversations before engaging clinicians, including handling typical objections and ensuring alignment with legal and compliance frameworks. The platform is designed to help reps prepare for multi‑touch sales cycles—often 15 or more interactions with a healthcare provider—by simulating those discussions and reinforcing compliant, patient‑centric messaging. While AI role‑playing tools exist in other sectors, PraxisPro differentiates itself by focusing exclusively on life sciences and using smaller, targeted datasets that aim to produce more contextually accurate training for this regulated environment. For executives at pharma, biotech, and medtech firms, the potential impact centers on higher-quality commercial execution, reduced compliance risk, and improved uptake of new therapies by ensuring field teams can communicate complex clinical value propositions clearly and consistently to healthcare providers.